The Translational
Pharmacogenetics Program (TPP) is a Pharmacogenomics Research Network
(PGRN)-led initiative with the goal to identify barriers and develop real-world
solutions to implement evidence-based pharmacogenetic tests in diverse
health care settings. The participating sites include 6 implementation
institutions (Universityof Maryland, University of Florida, St. Jude Children's
Research Hospital, Vanderbilt University, Mayo Clinic, and Ohio State
University), as well as PharmGKB which
serves a coordination and knowledge sharing and dissemination role and Pharmacogenomic
Ontology (PHONT) at the Mayo Clinic which provides data harmonization and
standardization support.
The TPP investigators has published the design manuscript in
Clin Pharmacol Ther this month. This paper discusses challenges and
implementation barriers to translation of pharmacogenomics in clinical
practice. Each implementation site institutes CLIA-based pharmacogenomics
testing, reports results in EHR for clinical decision and tracks summary
descriptions and implementation metrics to objectively evaluate the
effectiveness of implementation. TPP also creates "look up" tables
(posted on PharmGKB) which contain phenotype and clinical decision support
system information based on haplotypes and diplotypes. These tables “complement
the existing CPIC guidelines by providing therapy recommendations for a more
comprehensive coverage of pharmacogenetic test results. They represent the
current state of knowledge and demonstrate the range of observed results and
recommended actions across sites”.
Read more:
Shuldiner AR, Relling MV, Peterson JF, Hicks K, Freimuth RR,
Sadee W, Pereira NL, Roden DM, Johnson JA, Klein TE. Clin Pharmacol Ther.
2013 Mar 19. doi: 10.1038/clpt.2013.59.
